Sign In
Buy MBRX
$2.46
+0 (+0%)
At Close: Jun 03, 2026
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
08:31am, Thursday, 04'th Jun 2026
- Access the segment here
Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
08:30am, Friday, 15'th May 2026
Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding
12:41pm, Wednesday, 13'th May 2026
Moleculin Biotech Inc. (NASDAQ:MBRX) said it remains on track to unblind the first set of data from its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapse
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
08:00am, Wednesday, 13'th May 2026
Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of care First 45-subject data unblinding expected before June 30, 2026
Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
08:45am, Friday, 08'th May 2026
Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” o
Analyzing Moleculin Biotech (NASDAQ:MBRX) and Incyte (NASDAQ:INCY)
01:28am, Monday, 27'th Apr 2026
Incyte (NASDAQ: INCY - Get Free Report) and Moleculin Biotech (NASDAQ: MBRX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on
Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
08:25am, Thursday, 23'rd Apr 2026
Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
08:36am, Tuesday, 21'st Apr 2026
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidat
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile
08:36am, Tuesday, 07'th Apr 2026
Access the Moleculin CEO Corner here
Scalable Biotech Manufacturing Unlocks a $14B Market
09:15am, Friday, 27'th Mar 2026
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
08:31am, Monday, 23'rd Mar 2026
HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the 45th subject has been enrolled in its pivotal Phase
HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the year ended December 31, 2025 and pr
